ACTRN12619001641189已完成未知
Combating disordered eating and poor body image with the use of imagery rescripting among young women at risk of developing an eating disorder
Breakthrough Mental Health Research Foundation0 个研究点目标入组 130 人开始时间: 2019年11月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 17 Years 至 25 Years（—）
- 性别
- Female
入选标准
- •Females Flinders University undergraduates aged 17 -25 years, who were at risk of developing an eating disorder, as indicated by a score on the Weight Concern Scale (WCS; Killen et al., 1994) >= 47, considered a cut-off with good predictive validity for eating disorder cases (Jacobi, Abascal, & Taylor, 2004; Killen et al., 1994; 1996), were included in the study.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosismyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003415-98-HUIncyte Corporation212
进行中（未招募）
1 期
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial HypercholesterolemiaEUCTR2017-001903-60-DESanofi-aventis recherche & développement500
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, with Open-Label ExtensioBIPOLAR MANIAEUCTR2004-003781-14-ESJohnson and Johnson Pharmaceutical Research and Development, una división de Janssen-Cilag, S.A
进行中（未招募）
1 期
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)Extensive Stage Small Cell Lung Cancer (ED SCLC)EUCTR2016-003503-64-GBAbbvie Deutschland GmbH & Co. KG748
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT 126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsMedDRA version: 15.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's DiseaseEUCTR2011-004849-40-DEAbbVie Deutschland GmbH & Co. KG420